Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Summary

This is a multi-center, open-label, dose escalation study that will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of liposomal annamycin as a single agent for the treatment of subjects with AML that is refractory to or relapsed after standard induction therapy

Timeline

Start

2018-03-28

Primary completion

2020-01-14

Completion

2020-06-20

Drugs

Indications